Linked Life Data

1321654

Source:http://linkedlifedata.com/resource/pubmed/id/1321654

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1992-8-24
pubmed:abstractText
1. The effects of granisetron (160 micrograms kg-1 body weight) and haloperidol (3 mg) on psychometric performance and the EEG were investigated in a randomised, single-blind, crossover, placebo controlled study of 12 healthy male volunteers. 2. There was evidence that haloperidol impaired psychometric performance; however its effects on the EEG were not clear cut. In contrast there was very little evidence to suggest that granisetron had any impact on performance or the EEG. 3. The findings from this study suggest that granisetron does not impair daytime function and that it can be co-administered with haloperidol without producing unwanted synergistic effects.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
65-70
pubmed:dateRevised
2010-9-7
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG.
pubmed:affiliation
Human Pharmacology Unit, SmithKline Beecham Pharmaceuticals, Harlow, Essex.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial